New data on lecanemab to be presented at CTAD conference

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical ...

BioArctic: New data on lecanemab to be presented at CTAD conference

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials ...
Zacks.com on MSN

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3

ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD ...
Le Lézard

RAK Medical & Health Sciences University Selects Ellucian Student to Advance Digital Transformation and Enhance Student Experience

Ellucian, the leading higher education technology solutions provider, today announced that RAK Medical & Health Sciences ...
Le Lézard

Scientists Develop AxioMed Spinal Disc Replacement That Truly Mimics Healthy Human Disc -- A Game-Changer in Spine Surgery

A groundbreaking scientific milestone has been achieved in spine surgery with the publication of a new peer-reviewed ...
TipRanks on MSN

BioArctic’s Lecanemab Data to be Unveiled at CTAD Conference

BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement. BioArctic AB announced that its partner Eisai will present new data on their ...

Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Diseas…

Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings ...

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, ...